Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Abstract Background Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	S. B. Patil, M. Tamirat, K. Khazhidinov, E. Ardizzoni, M. Atger, A. Austin, E. Baudin, M. Bekhit, S. Bektasov, E. Berikova, M. Bonnet, R. Caboclo, M. Chaudhry, V. Chavan, S. Cloez, J. Coit, S. Coutisson, Z. Dakenova, B. C. De Jong, C. Delifer, S. Demaisons, J. M. Do, D. Dos Santos Tozzi, V. Ducher, G. Ferlazzo, M. Gouillou, U. Khan, M. Kunda, N. Lachenal, A. N. LaHood, L. Lecca, M. Mazmanian, H. McIlleron, M. Moreau, M. Moschioni, P. Nahid, E. Osso, L. Oyewusi, S. Panda, A. Pâquet, P. Thuong Huu, L. Pichon, M. L. Rich, P. Rupasinghe, N. Salahuddin, E. Sanchez Garavito, K. J. Seung, G. E. Velásquez, M. Vallet, F. Varaine, F. J. Yuya-Septoh, C. D. Mitnick, L. Guglielmetti
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2023-11-01
Ráidu:	Trials
Fáttát:	Fluroquinolone-resistant Pre-XDR TB Multidrug-resistant Rifampicin-resistant MDR-TB RR-TB
Liŋkkat:	https://doi.org/10.1186/s13063-023-07701-6
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!